

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
29 July 2021 (29.07.2021)



(10) International Publication Number
WO 2021/150985 A1

(51) International Patent Classification:

A61K 31/135 (2006.01) A61P 25/24 (2006.01)

(21) International Application Number:

PCT/US2021/014748

(22) International Filing Date:

22 January 2021 (22.01.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/964,598 22 January 2020 (22.01.2020) US
63/079,791 17 September 2020 (17.09.2020) US

(71) Applicant: SEELOS THERAPEUTICS, INC. [US/US];
300 Park Avenue, 12th Floor, New York, New York 10022
(US).

(72) Inventors; and

(71) Applicants: MEHRA, Raj [US/US]; 300 Park Avenue,
12th Floor, New York, New York 10022 (US). WHITAK-
ER, Timothy [US/US]; 300 Park Avenue, 12th Floor, New
York, New York 10022 (US).

(74) Agent: BATES, Caleb A. et al.; Fish & Richardson P.C.,
P.O. Box 1022, Minneapolis, Minnesota 55440-1022 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(54) Title: REDUCING SIDE EFFECTS OF NMDA ANTAGONISTS

(57) Abstract: The present disclosure relates to compositions comprising racemic ketamine, or a pharmaceutically acceptable salt thereof, for use in treating psychiatric disorders such as suicidality, suicidal ideation, major depressive disorder, treatment-resistant depression, and post-traumatic stress disorder.



WO 2021/150985 A1